| 李磊.生血宝合剂联合重组人促红细胞生长素治疗化疗相关性贫血的临床研究李磊 宋海斌 钟敏钰 湖北省武汉市中西医结合医院[J].实用中西医结合临床,2016,16(9): |
| 生血宝合剂联合重组人促红细胞生长素治疗化疗相关性贫血的临床研究李磊 宋海斌 钟敏钰 湖北省武汉市中西医结合医院 |
| A Clinical Study on Treatment of Chemotherapy-related Anemia with Shengxuebao Mixture Combined with Recombinant Human ErythropoietinLi Lei, Song Haibin, Zhong Minyu, Wuhan Hospital of Traditional Chinese Western Medicine |
| 投稿时间：2016-06-21 修订日期：2016-07-16 |
| DOI： |
| 中文关键词: 生血宝合剂 重组人促红细胞生长素 化疗相关性贫血 |
| 英文关键词: Shengxuebao Mixture, Recombinant human erythropoietin, chemotherapy-related anemia |
| 基金项目: |
|
| 摘要点击次数: 765 |
| 全文下载次数: 441 |
| 中文摘要: |
| 目的：观察生血宝合剂联合重组人促红细胞生长素(rHuEPO)治疗化疗相关性贫血的临床疗效。方法：将纳入的155例患者随机分为两组,治疗组(78例)口服生血宝合剂(15ml/次,3次/日)配合rHuEPO皮下注射(EPO 150u/kg ,皮下注射 ,3次/周),对照组(77例)仅rHuEPO皮下注射,8周后评价患者治疗前后血红蛋白(Hb)均值变化、贫血治疗的临床有效率、以数字评分量表(NRS评分)评估患者生活质量。结果：治疗第2、4、6、8周治疗组患者的Hb值水平与对照组比较,差异有统计学意义(p<0.05),且两组均较治疗前升高(p<0.05)；贫血治疗有效率治疗组为82.1%,对照组为64.9%,差异有统计学意义(p<0.05)；治疗后两组NRS评分分别为30±5和60±7,差异有统计学意义(p<0.05)。结论：生血宝合剂联合EPO治疗化疗相关贫血疗效确切,明显改善患者的生活质量。 |
| 英文摘要: |
| Objective: To observe clinical effect of Shengxuebao Mixture combined with Recombinant Human Erythropoietin (rHuEPO) on chemotherapy-related anemia. Method: 155 patients admitted in our hospital were randomly divided into two groups – the Treatment Group and the Control Group. The Treatment Group (78 patients) were administered with Shengxuebao Mixture orally (15ml each time, 3 times per day) and with rHuEPO hypodermically (150u/kg, 3 times per week); while the Control Group (77 patients) were only administered with rHuEPO hypodermically. After 8 weeks, evaluation of mean values of hemoglobin (Hb) and clinical effectiveness ratio of anemia treatment were made for patients. And the Numeric Rating Scale was used to evaluate Patients’ life quality. Result: In week 2, 4, 6 and 8, the difference of Hb values between the Treatment Group and the Control Group was statistically significant (p<0.05), and Hb values in both groups have increased (p<0.05); the effectiveness ratio of anemia treatment in the Treatment Group was 82.1%, while the figure in the Control Group was 64.9%, and the difference was statistically significant (p<0.05); After treatment, NRS ratings for the two groups were 30±5 and 60±7 respectively, and the difference was statistically significant (p<0.05); Conclusion: Shengxuebao Mixture combined with Recombinant Human Erythropoietin (rHuEPO) has evident effect on chemotherapy-related anemia and can improve patients’ life quality significantly. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
